Xencor, Inc. — 2014 Form 10-K
Reporting period: Fiscal year ended December 31, 2014. This is an annual report, not a standalone fourth-quarter filing; quarterly figures are noted where relevant. Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies through its XmAb platform. It had no products approved for sale and generated no product-sale revenue.
Financial performance and position
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Revenue | $9.52 million | $10.17 million |
| Research and development expense | $18.52 million | $17.00 million |
| General and administrative expense | $7.46 million | $3.69 million |
| Operating loss | $16.46 million | $10.52 million |
| Net loss | $16.42 million | $60.26 million |
| Operating cash used | $21.35 million | $5.45 million |
| Cash and cash equivalents at year-end | $54.65 million | $77.98 million |
- Revenue consisted of collaboration, licensing and milestone income. The largest reported item was $6.9 million from Amgen, including $5.2 million recognized when the XmAb5871 collaboration ended.
- Cash used in investing activities was $2.28 million; financing provided $0.31 million. Cash declined by $23.33 million during 2014.
- Year-end working capital was $51.55 million; total assets were $67.82 million and stockholders’ equity was $59.29 million. Total liabilities were $8.53 million, including $4.59 million of deferred revenue. No material borrowing balance was reported; capital lease obligations were negligible.
- No meaningful product gross margin is reported because the company had no product sales. The filing does not provide a clear operating-margin measure beyond the reported operating loss.
- Fourth-quarter 2014 revenue was $5.66 million and net loss was $1.35 million, compared with revenue of $1.75 million and net loss of $3.70 million in fourth-quarter 2013. The 2014 quarter’s revenue included the Amgen termination-related recognition.
Material changes versus prior periods
- Revenue decreased 6% year over year, as lower milestone income (down $5.1 million) and licensing revenue were partly offset by higher research collaboration revenue, including Amgen-related recognition.
- R&D expense rose $1.5 million, chiefly reflecting $5.1 million of new bispecific-program spending, partly offset by lower XmAb5871 and XmAb5574/MOR208 costs. G&A expense increased $3.8 million, including higher public-company, staffing, professional-fee and patent-abandonment costs.
- Net loss narrowed substantially from 2013, primarily because 2013 included a $48.6 million noncash loss on settlement of convertible notes. Excluding that unusual item, 2014 operating loss increased as expenses grew and revenue remained below operating costs.
- Operating cash use increased by $15.9 million, affected by lower deferred revenue, higher receivables and lower payables/accruals. The 2013 cash balance had benefited from the IPO and preferred-stock financing.
Business developments, outlook and risks
- Pipeline: XmAb5871 completed a Phase 1b/2a rheumatoid arthritis trial; Xencor ended the Amgen collaboration in October 2014, regained worldwide rights and shifted its planned focus toward IgG4-related disease. The filing describes January 2015 trial results as subsequent information: in an evaluable Phase 2a group, 5 of 15 treated patients achieved DAS28-CRP remission or low disease activity versus none of eight placebo patients. Two treatment-related serious adverse events were reported, including an infusion reaction and venous thrombosis.
- XmAb7195: A Phase 1a trial began in 2014. January 2015 interim data reported rapid free-IgE reductions; transient, asymptomatic thrombocytopenia at 3.0 mg/kg was dose-limiting, and urticaria was also observed. A Phase 1b study was planned for 2015, subject to safety assessment.
- Bispecifics: Xencor selected XmAb14045 (CD123xCD3) for IND-enabling studies and manufacturing preparation, with clinical testing planned for 2016. The company also reported preclinical results for CD20xCD3 and CD38xCD3 candidates.
- Partnerships: A Novo Nordisk discovery collaboration was signed in December 2014. Xencor reported a $2.5 million upfront payment received in January 2015 and annual research funding of $1.6 million over an initial two-year term; potential development, regulatory and sales milestones total up to $167.3 million, plus mid-single-digit royalties if a product is commercialized. These are contingent amounts, not assured revenue.
- Runway and funding: Management expected approximately $28 million of cash at year-end 2015 and believed existing cash and certain potential milestones would fund planned operations through the end of 2016. The company cautioned that estimates may prove inaccurate and that additional financing or partnerships will be needed to complete development. It had an accumulated deficit of $244.0 million and expected continued losses.
- Principal risks: Clinical and regulatory failure or delay; safety findings; reliance on partners and contract manufacturers; financing needs and potential dilution; uncertain milestone and royalty income; competition; and patent, licensing and intellectual-property exposure. Xencor also disclosed potential third-party patent issues relating to its candidates and reliance on external manufacturing.
- Unusual/control items: The $48.6 million 2013 convertible-note settlement loss was a major nonrecurring accounting item. A material weakness in revenue-recognition controls identified for 2013 was reported as remediated; management concluded internal control over financial reporting was effective at December 31, 2014. The auditor did not provide an internal-control audit opinion, consistent with the emerging-growth-company exemption.
Most important facts for investors to verify
- Whether clinical efficacy and safety findings for XmAb5871 and XmAb7195 are confirmed in larger, later-stage trials, particularly the thrombocytopenia and serious adverse events.
- Actual cash burn, milestone receipts and whether the stated runway through 2016 remains achievable as development spending increases.
- Progress and timing of XmAb14045 IND-enabling work, manufacturing readiness and the planned clinical start.
- Whether partners advance licensed programs and whether contingent milestones, royalties or Novo research funding are earned and collected as expected.
- Resolution of manufacturing, licensing and third-party patent risks, and continued effectiveness of revenue-recognition controls.